Marrow proliferation as a cause of hearing loss in beta-thalassaemia major.
OBJECTIVE
The aim of this report was to highlight the fact that hearing loss in thalassaemia patients can be related to marrow expansion affecting the ossicles, resulting in a conductive loss.


METHODS
A six-year-old boy with transfusion-dependent beta-thalassaemia developed a unilateral hearing loss shortly after commencing desferrioxamine therapy. Ototoxicity was assumed, but the deficit was later found to be of a conductive nature, due to marrow proliferation within the ossicular chain as a consequence of the disease process--a phenomenon previously unreported in the literature.


CONCLUSIONS
It is important to elucidate the precise nature of new onset hearing loss in patients receiving iron chelation therapy, in order to avoid unnecessary cessation of much needed medication, on the assumption of ototoxicity.
Thio
D
D
Department of Otolaryngology, Musgrove Park Hospital, Taunton, UK. daniel.thio@yahoo.co.uk
Prasad
V
V
Anslow
P
P
Lennox
P
P
D001855:Bone Marrow Diseases / Q000150:complications*; D002648:Child; D003676:Deferoxamine / Q000009:adverse effects*; D034381:Hearing Loss / Q000139:chemically induced*; D006801:Humans; D008297:Male; D017262:Siderophores / Q000009:adverse effects*; D017086:beta-Thalassemia / Q000188:drug therapy*
D017262:Siderophores; D003676:Deferoxamine